---
title: "NRC Health 2026: Revenue $35.39M, EPS ($0.15) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294858231.md"
description: "NRC Health reported Q2 2026 results with revenue of $35.39M, up 4% YoY, but posted a net loss of ($3.28M) and diluted EPS of ($0.15), compared to a minor loss in the prior year. Revenue growth was driven by recurring revenue and new customers. TRCV rose 11% to $151.9M. Increased investments in technology, R&D, and non-recurring stock-based compensation impacted operating margins."
datetime: "2026-08-04T18:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294858231.md)
  - [en](https://longbridge.com/en/news/294858231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294858231.md)
generator: "portal-rs"
---

# NRC Health 2026: Revenue $35.39M, EPS ($0.15) — 10-Q Summary

NRC Health reported results for the quarter ended 2026 with revenue of $35.39M, up 4% from $34.04M a year earlier, and a net loss of ($3.28M) versus a loss of ($106K) in the prior-year quarter; diluted EPS was ($0.15) compared with ($0.01) a year ago.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$35.39M

$34.04M

4%

Net income²

($3.28M)

($106K)

(2997.2%)

Diluted EPS³

($0.15)

($0.01)

(1400%)

*¹ Reported as “Revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Earnings (loss) per share of common stock”.*

**Business Highlights**

-   Revenue growth of about 4% year-over-year was driven by higher recurring revenue from existing customers and additions of net new customers.
-   The company introduced approximately $0.7M of contra‑revenue related to agent arrangements, reflecting increased third‑party solution facilitation.
-   Total recurring contract value (TRCV) rose 11% YoY to $151.9M, indicating a stronger contracted recurring pipeline and improved revenue visibility.
-   Management increased technology and delivery investments, including higher contractor, subscription and R&D costs; headquarters renovation completed in June 2025.
-   Executive equity amendments and related transition costs raised stock‑based compensation and affected operating margins; these were characterized as non‑recurring items.

Original SEC Filing: NRC HEALTH \[ NRC \] - 10-Q - Aug. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NRC.US](https://longbridge.com/en/quote/NRC.US.md)

## Related News & Research

- [KLAS First Look: NRC Health Rounding Earns 91.6 Overall Performance Score | NRC Stock News](https://longbridge.com/en/news/297820444.md)
- [NRC Health 1Q 2026: Revenue $34.8M, EPS $0.14— 10-Q Summary](https://longbridge.com/en/news/285407459.md)
- [UPS announces R$ 0.36 dividend per unit for Q3 2026](https://longbridge.com/en/news/298324635.md)
- [Realty Income raises monthly dividend to USD 0.27 a share](https://longbridge.com/en/news/298359660.md)
- [Pfizer announces Q3 2026 dividend of R$ 0.37 per unit for BRPFIZBDR 006](https://longbridge.com/en/news/297929469.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**